Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$0.87 USD
-0.01 (-0.91%)
Updated May 15, 2024 04:00 PM ET
After-Market: $0.84 -0.03 (-3.67%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/12/24 |
---|---|
Current Quarter | -0.20 |
EPS Last Quarter | -0.28 |
Last EPS Surprise | -40.00% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -0.90 |
Next Year | -0.90 |
EPS (TTM) | -1.60 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.20 | -0.20 | -0.90 | -0.90 |
# of Estimates | 2 | 2 | 2 | 2 |
Most Recent Consensus | -0.20 | -0.20 | -1.20 | -1.00 |
High Estimate | -0.20 | -0.20 | -0.60 | -0.80 |
Low Estimate | -0.20 | -0.20 | -1.20 | -1.00 |
Year ago EPS | -0.72 | -0.34 | -2.06 | -0.90 |
Year over Year Growth Est. | 72.22% | 41.18% | 56.31% | 0.00% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 1 | 1 | 1 |
Up Last 60 Days | 1 | 2 | 2 | 1 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 0 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.20 | -0.20 | -0.90 | -0.90 |
7 Days Ago | -0.20 | -0.20 | -0.90 | -0.90 |
30 Days Ago | -0.20 | -0.30 | -1.20 | -1.50 |
60 Days Ago | -0.30 | -0.40 | -1.30 | -2.00 |
90 Days Ago | -0.40 | -0.40 | -1.40 | -1.60 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.20 | -0.20 | -0.60 | -0.80 |
Zacks Consensus Estimate | -0.20 | -0.20 | -0.90 | -0.90 |
Earnings ESP | 0.00% | 0.00% | 33.33% | 11.11% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.28 | -0.26 | -0.34 | -0.72 | NA |
Estimate | -0.20 | -0.40 | -0.60 | -0.80 | NA |
Difference | -0.08 | 0.14 | 0.26 | 0.08 | 0.10 |
Surprise | -40.00% | 35.00% | 43.33% | 10.00% | 12.08% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more